{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:07:41Z","timestamp":1787069261310,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Introduction<\/jats:title>\n Interleukin 2 (IL-2) is essential for immune system activation. To reduce toxicity and prevent the activation of regulatory T cells (T-regs), a novel IL-2 variant containing 4-point mutations that prevent its interaction with the alpha chain of the receptor was designed. In preclinical studies, the no-alpha mutein preferentially stimulate CD8-T cells and natural killer (NK) cells compared to Tregs. Mutein also showed greater antitumor capacity than the native molecule in several tumor models.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients with advanced solid tumors were included in a single-arm dose-escalation Phase I trial. The objectives of this study were to evaluate the safety and identify the recommended phase 2 dose. The effects on the most important immune subpopulations and preliminary objective response were also assessed. The protocol was listed in the National Registry for Clinical Trials (\n https:\/\/rpcec.sld.cu\/ensayos\/RPCEC00000234-En<\/jats:uri>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results and Discussion<\/jats:title>\n In this phase I trial, 13 patients with advanced cancer were treated with five dose levels of IL-2 mutein, from 300 to 2400 IU\/kg. The treatment was safe, and the maximum tolerated dose was not reached. Dose escalation did not continue, as a greater clinical and pharmacodynamic effect was observed at intermediate doses. One patient developed a possibly related serious event consisting on ventricular dysfunction and pneumonitis. No toxic deaths or vascular leak syndromes were detected, and the most frequent toxicities were chills, fever, and tachycardia. After treatment, most patients experienced an expansion of the total lymphocyte counts and the CD8-T cells and NK cells.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration<\/jats:title>\n \n https:\/\/rpcec.sld.cu\/ensayos\/RPCEC00000234-En<\/jats:uri>\n , identifier RPCEC00000234.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1589042","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T02:08:41Z","timestamp":1747966121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["First-in-human evaluation of a no-alpha interleukin\u20132 mutein: safety and preliminary pharmacodynamic and clinical effect"],"prefix":"10.3389","volume":"16","author":[{"given":"Iraida","family":"Caballero Aguirrechu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braulio","family":"Mestre Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Luis","family":"Soriano Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Lim Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Soto Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Fleites Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daines","family":"Mari\u00f1o de la Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geidy","family":"Vega Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Carolina","family":"\u00c1vila P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivis","family":"Mendoza Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garc\u00eda L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Tarinas Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"D\u00edaz Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuris","family":"Led\u00f3n Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sum Lai","family":"Lozada Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanelda","family":"Garc\u00eda Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Alv\u00e1rez Lobaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Alv\u00e1rez Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lorenzo-Luaces Alv\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Crombet Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Carmenate Portilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalet","family":"Le\u00f3n Monz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1366315","article-title":"Immunotherapy of cancers comes of age","volume":"13","author":"Yousefi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/003591571000301601","article-title":"The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus)","volume":"3","author":"Coley","year":"1910","journal-title":"Proc R Soc Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.026","article-title":"A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment","volume":"39","author":"Lamm","year":"2021","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"key":"B5","first-page":"381","article-title":"Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma","volume":"84","author":"Mansh","year":"2011","journal-title":"Yale J Biol med"},{"key":"B6","first-page":"234","article-title":"Pembrolizumab: first in class for treatment of metastatic melanoma","volume":"6","author":"Barnhart","year":"2015","journal-title":"J\u00a0advanced practitioner oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","article-title":"Clinical landscape of LAG-3-targeted therapy","volume":"14","author":"Chocarro","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell Malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944927","article-title":"First regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs)\u2013lifileucel (Amtagvi)","volume":"30","author":"Parums","year":"2024","journal-title":"Med Sci Monitor: Int Med J Exp Clin Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2410","article-title":"Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy","volume":"14","author":"Fyfe","year":"1996","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0909384107","article-title":"IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25","volume":"107","author":"Letourneau","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.1996.d01-430.x","article-title":"Adhesion molecule expression and leucocyte trafficking following immunotherapy with recombinant interleukin-2","volume":"28","author":"Miles","year":"1996","journal-title":"Histopathology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201895","article-title":"Human IL-2 mutein with higher antitumor efficacy than wild type IL-2","volume":"190","author":"Carmenate","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974188","article-title":"The antitumor effect induced by an IL-2 \u2018no-alpha\u2019 mutein depends on changes in the CD8(+) T lymphocyte\/Treg cell balance","volume":"13","author":"Carmenate","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091316","article-title":"Rethinking oncologic treatment strategies with interleukin-2","volume":"12","author":"Ko","year":"2023","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/imammb\/dqw021","article-title":"The effects of interleukin-2 on immune response regulation","volume":"35","author":"Waters","year":"2018","journal-title":"Math Med Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.10.4711","article-title":"Cancer vaccines: the interleukin 2 dosage effect","volume":"92","author":"Schmidt","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41698-024-00641-7","article-title":"Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab","volume":"8","author":"Gogas","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02082","article-title":"Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: A phase III randomized study (PIVOT-09)","volume":"42","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T02:08:43Z","timestamp":1747966123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1589042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1589042"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1589042","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"article-number":"1589042"}}